Phase 2 Trial of Ruxolitinib JAK1 Inhibitor in Combination Therapy for Glioblastoma

This randomized Phase 2 trial evaluates the safety and effectiveness of adding ruxolitinib to standard radiation and temozolomide in patients with newly diagnosed glioblastoma. The study features two treatment arms with drug administration during radiation therapy followed by maintenance, sponsored by Baptist Health South Florida.